hMSC platform for biological products manufacturing

Project: Internal grants/own callsProjects

Project Details

Description

"
The main objective is to perform a preliminary study to explore the potential of the technology described in order to obtain some evidences that would be used to support the submission of future projects to public/private calls.
The proposal arises based on the following facts and premises:
- Different products with different features can be obtained from Mesenchymal Stem Cells (hMSC) from the cells itself (cell and tissue therapy), protein complexes (exosomes) or proteins (novel platform to be develop therein this proposal)
- Some cytokines and other small molecules are actually produced in bacteria .Mid-term MSC culturing platforms for cell therapy have already been described.
- MSC have already been engineered for tracking purposes in cell and tissue therapy.
- hMSC express proteins with human glycosylation patterns, what could increase the activity of such proteins.
Mains Objective:
Develop a GMP compliant platform for hMSC expansion as a common backbone of the bioprocess platform for the different final product applications (cells, protein complexes and heterologous proteins)
Construction of stable hMSC lines for heterologous protein expression. Bioprocess development for cytokines and other small molecules manufacturing with human glycosylation patterns.
Specific objectives phase 1:
1. Definition of a mid-long term culturing platform of hMSCs GMP compliant-like based on 3D cultures (commercial and home-synthetized microcarriers)
2. Determination of suitable selection markers for hMSC clone selection.
3. Construction of rhMSC producing cell lines.
Specific objectives phase 2:
4. Study the potential of controlling the senescence effect of hMSC to be used as a valuable tool for high cell density production systems (perfusion systems).
5. Explore the possibility of generating immortal cell lines while preserving the possibility of inducing senescence effect.
6. Explore the possibility of developing high cell density cultures for protein production
"

Layman's description

"
The main objective is to perform a preliminary study to explore the potential of the technology described in order to obtain some evidences that would be used to support the submission of future projects to public/private calls.
The proposal arises based on the following facts and premises:
- Different products with different features can be obtained from Mesenchymal Stem Cells (hMSC) from the cells itself (cell and tissue therapy), protein complexes (exosomes) or proteins (novel platform to be develop therein this proposal)
- Some cytokines and other small molecules are actually produced in bacteria .Mid-term MSC culturing platforms for cell therapy have already been described.
- MSC have already been engineered for tracking purposes in cell and tissue therapy.
- hMSC express proteins with human glycosylation patterns, what could increase the activity of such proteins.
Mains Objective:
Develop a GMP compliant platform for hMSC expansion as a common backbone of the bioprocess platform for the different final product applications (cells, protein complexes and heterologous proteins)
Construction of stable hMSC lines for heterologous protein expression. Bioprocess development for cytokines and other small molecules manufacturing with human glycosylation patterns.
Specific objectives phase 1:
1. Definition of a mid-long term culturing platform of hMSCs GMP compliant-like based on 3D cultures (commercial and home-synthetized microcarriers)
2. Determination of suitable selection markers for hMSC clone selection.
3. Construction of rhMSC producing cell lines.
Specific objectives phase 2:
4. Study the potential of controlling the senescence effect of hMSC to be used as a valuable tool for high cell density production systems (perfusion systems).
5. Explore the possibility of generating immortal cell lines while preserving the possibility of inducing senescence effect.
6. Explore the possibility of developing high cell density cultures for protein production
"
StatusFinished
Effective start/end date1/01/1831/12/18